AgomAb Therapeutics (AGMB) Financial statements

Net income was -63M EUR.

Key figures

Free cash flow was -52M EUR.

Fiscal 2023–2025, in EUR.

AgomAb Therapeutics (AGMB) income statement by fiscal year, EUR
EUR	FY2023	FY2024	FY2025
Research and development	26M EUR	39M EUR	49M EUR
Selling, general and admin	6M EUR	10M EUR	13M EUR
Operating income	-31M EUR	-48M EUR	-59M EUR
Interest expense	86,000 EUR	357,000 EUR	133,000 EUR
Pre-tax income	-12M EUR	-46M EUR	-63M EUR
Income tax	-619,000 EUR	4,000 EUR	—
Net income	-11M EUR	-46M EUR	-63M EUR
EPS (diluted)	-35.63 EUR	-107.09 EUR	-143.22 EUR
Diluted shares	1M	1M	1M

AgomAb Therapeutics (AGMB) balance sheet by fiscal year, EUR
EUR	FY2023	FY2024	FY2025
Cash and short-term investments	122M EUR	171M EUR	117M EUR
Total current assets	—	174M EUR	121M EUR
Property, plant and equipment	—	619,000 EUR	503,000 EUR
Goodwill	—	9M EUR	9M EUR
Total assets	—	206M EUR	154M EUR
Total current liabilities	—	9M EUR	19M EUR
Total liabilities	—	18M EUR	23M EUR
Shareholders' equity	151M EUR	188M EUR	131M EUR
Net debt	-122M EUR	-171M EUR	-86M EUR

AgomAb Therapeutics (AGMB) cash flow by fiscal year, EUR
EUR	FY2023	FY2024	FY2025
Operating cash flow	-25M EUR	-47M EUR	-52M EUR
Capital spending	—	675,000 EUR	4,000 EUR
Free cash flow	—	-48M EUR	-52M EUR
Stock-based compensation	2M EUR	1M EUR	5M EUR

AgomAb Therapeutics's ROE is higher than 27% of Healthcare companies and 9% of the 3,458 companies with an ROE figure.

AgomAb Therapeutics (AGMB) percentile ranks: share of companies with a lower figure
Higher than	Healthcare	All stocks
ROE	27%	9%

-52M EUR in fiscal 2025 (operating cash flow minus capital spending).

From AgomAb Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.